Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.220
+0.010 (0.83%)
At close: Aug 21, 2026, 4:00 PM EDT
1.230
+0.010 (0.82%)
After-hours: Aug 21, 2026, 7:39 PM EDT

Spero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4766.847.98103.7853.5118.26
Revenue Growth
-3.25%39.24%-53.77%93.95%193.10%95.67%
Cost of Revenue
20.5338.4796.7651.4447.5964.53
Gross Profit
26.4728.34-48.7852.345.92-46.27
Selling, General & Admin
19.8521.1823.725.5536.4841.7
Operating Expenses
19.8521.1823.725.5536.4841.7
Operating Income
6.617.16-72.4826.79-30.57-87.97
Interest Expense
-----2.61-1.94
Interest & Investment Income
1.622.514.743.941.110.35
Other Non Operating Income (Expenses)
-00.010.06-0.010.86-0.19
EBT Excluding Unusual Items
8.239.68-67.6930.71-31.2-89.76
Merger & Restructuring Charges
--0.26-0.88--11.63-
Asset Writedown
-0.59-0.59--5.31--
Other Unusual Items
-----3.58-
Pretax Income
7.648.83-68.5725.4-46.42-89.76
Income Tax Expense
0.260.26-2.6--
Earnings From Continuing Operations
7.388.57-68.5722.81-46.42-89.76
Net Income
7.388.57-68.5722.81-46.42-89.76
Net Income to Common
7.388.57-68.5722.81-46.42-89.76
Net Income Growth
------
Shares Outstanding (Basic)
575654533831
Shares Outstanding (Diluted)
605954533831
Shares Change
9.05%9.25%1.98%40.98%21.65%38.01%
EPS (Basic)
0.130.15-1.270.43-1.23-2.91
EPS (Diluted)
0.130.15-1.270.43-1.23-2.91
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
19.58-12.62-23.44-33-7.73-64.35
Free Cash Flow Per Share
0.33-0.21-0.43-0.62-0.21-2.08
Gross Margin
56.31%42.42%-101.67%50.43%11.06%-253.45%
Operating Margin
14.07%10.72%-151.08%25.81%-57.13%-481.87%
Profit Margin
15.71%12.83%-142.91%21.98%-86.74%-491.65%
Free Cash Flow Margin
41.66%-18.90%-48.86%-31.79%-14.45%-352.47%
EBITDA
-7.16-72.4827.15-29.7-87.33
EBITDA Margin
-10.72%-151.08%26.16%-55.50%-
D&A For EBITDA
-000.370.870.65
EBIT
6.617.16-72.4826.79-30.57-87.97
EBIT Margin
14.07%10.72%-151.08%25.81%-57.13%-
Effective Tax Rate
3.41%2.96%-10.23%--
Revenue as Reported
4766.847.98103.7853.5118.26
SEC Filings: 10-K · 10-Q